Alpha Tau Medical (NASDAQ:DRTS) Shares Up 0.5% - Still a Buy?

Shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) were up 0.5% during mid-day trading on Wednesday . The company traded as high as $3.08 and last traded at $2.99. Approximately 16,532 shares traded hands during trading, a decline of 67% from the average daily volume of 50,162 shares. The stock had previously closed at $2.97.

Analyst Ratings Changes

Separately, HC Wainwright reissued a "buy" rating and issued a $9.00 price objective on shares of Alpha Tau Medical in a research note on Tuesday, April 29th.

Alpha Tau Medical Stock Performance

The company has a current ratio of 5.81, a quick ratio of 5.81 and a debt-to-equity ratio of 0.10. The company has a fifty day moving average of $2.88 and a two-hundred day moving average of $2.99.

Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last released its quarterly earnings results on Monday, May 19th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.02. On average, analysts forecast that Alpha Tau Medical Ltd. will post -0.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Alpha Tau Medical

Several institutional investors and hedge funds have recently made changes to their positions in DRTS. Levin Capital Strategies L.P. boosted its holdings in Alpha Tau Medical by 2.3% in the fourth quarter. Levin Capital Strategies L.P. now owns 314,514 shares of the company's stock valued at $975,000 after acquiring an additional 7,189 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of Alpha Tau Medical in the 1st quarter worth approximately $53,000. Northern Trust Corp boosted its stake in shares of Alpha Tau Medical by 112.6% in the 4th quarter. Northern Trust Corp now owns 48,666 shares of the company's stock valued at $151,000 after purchasing an additional 25,770 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Alpha Tau Medical by 188.7% in the 4th quarter. Renaissance Technologies LLC now owns 41,000 shares of the company's stock valued at $127,000 after purchasing an additional 26,800 shares during the last quarter. Finally, Kovitz Investment Group Partners LLC increased its position in shares of Alpha Tau Medical by 601.4% during the first quarter. Kovitz Investment Group Partners LLC now owns 226,320 shares of the company's stock worth $568,000 after buying an additional 194,055 shares during the period. Institutional investors and hedge funds own 2.65% of the company's stock.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.